Similarly, SIRT2 inhibitors have shown promise in targeting ATRX (alpha-thalassemia mental retardation X-linked)-deficient gliomas, highlighting its role in driving oncogenic phenotypes in specific tumor subtypes [72]. The gene discussed is SIRT2; the disease is central nervous system cancer.